Other languages ORIC Pharmaceuticals, Inc.

Equities

ORIC

US68622P1093

Market Closed - Nasdaq Other stock markets 01:30:00 27/04/2024 am IST			5-day change	1st Jan Change
8.07 ^USD	+5.22%		-12.19%	-12.28%

15/04	ORIC Pharmaceuticals Doses First Patients in Expansion Groups in Phase 1b Trial of ORIC-114 to Treat Lung Cancer	MT
15/04	ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC	16/04
ORIC Pharmaceuticals, Inc Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research Annual Meeting	08/04
ORIC Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	12/03
ORIC Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	12/03
Oric Pharmaceuticals Insider Sold Shares Worth $648,380, According to a Recent SEC Filing	09/03
Oric Pharmaceuticals Insider Sold Shares Worth $489,346, According to a Recent SEC Filing	09/02
ORIC Pharmaceuticals Launching $125 Million Private Placement	22/01
ORIC Pharmaceuticals, Inc. Provides Initial Phase 1B Data for Oric-944	08/01
ORIC Pharmaceuticals Says Initial Phase 1 Dose Escalation Data for ORIC-533 Shows Evidence of Clinical Antimyeloma Activity	12/12
ORIC Pharmaceuticals, Inc. Announces Initial Data from the Ongoing ORIC-533 Phase 1 Dose Escalation Trial in Patients with Relapsed/Refractory Multiple Myeloma At the 65th American Society of Hematology Annual Meeting	11/12
ORIC Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	07/11
ORIC Pharmaceuticals, Inc. Announces Initial Phase 1 Dose Escalation Data of ORIC-114 in Patients with EGFR and HER2 Exon 20 Mutations	21/23/21
ORIC Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/23/11
ORIC Pharmaceuticals Launches $85 Million Private Placement; Shares Extend Gains Premarket	27/23/27
ORIC Pharmaceuticals Launches $85 Million Private Placement; Shares Rise	26/23/26
ORIC Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	09/23/09
2022, une année boursière toute pourrie	02/23/02
En Direct des Marchés : Airbus, Atos, Alstom, Alten, Valneva, Chevron, ING, Ferrovial...	02/23/02
Pfizer Discloses 12% Stake in ORIC Pharmaceuticals	30/22/30
Sector Update: Healthcare Stocks Finish Narrowly LowerThursday	23/22/23

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages ORIC Pharmaceuticals, Inc.

Equities

ORIC

US68622P1093

Other languages

Filters